Triple-Negative Breast Cancer: Overview, Treatment, and More.
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with unfavorable outcome. It is urgent to explore novel biomarkers and potential therapeutic targets in this malignancy. Increasing knowledge of long noncoding RNAs (lncRNAs) significantly deepens our understanding of cancer biology. Here, we sequenced eight paired TNBC tumor tissues and non-cancerous tissues, and.
A new preclinical study on triple negative breast cancer (TNBC) reports that an experimental polo-like kinase 1 (PLK1) inhibitor shrank tumor four times more powerfully when used along with.
While the finding applies to all breast cancers, it is particularly relevant for women with basal (triple negative cancer) breast cancer, for which there is no current targeted therapy. The good news is that drugs for silencing hedgehog are already undergoing Phase 2 clinical trials in other cancer types. Clinical Associate Professor Sandra O.
Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor-2 (HER2) overexpression. It shows substantial overlap with basal-type and BRCA1-related breast cancers, both of which also have aggressive.
Triple-negative breast cancer lacks these three targets.. Breast cancer research at Fred Hutch is all-encompassing. Our scientists pinpoint new risk factors and improve detection. We delve into the genetic drivers of the disease, finesse current therapies and develop new ones. Our scientists strive to enhance survivorship and patient outcomes. And we work to develop curative therapies for.
Research Paper cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer Joohyuk Sohn1,2, Shuying Liu 1,. Triple-negative breast cancer Introduction Triple-negative breast cancer (TNBC) comprises 15% of breast cancers, and today has the poorest sur-vival outcome of all breast cancer subtypes. Due to its heterogeneity, TNBC lacks validated therapeutic tar-gets.
SAN FRANCISCO—Women with triple-negative breast cancer (HER2-negative, progesterone-receptor-negative, and estrogen-receptor negative) who have a complete pathological response after neoadjuvant chemotherapy have a better prognosis than those who have residual disease after treatment. Until now, however, investigators have not examined whether all residual disease is equal.